Action 6
Committed by:
Prioritize PADO products in research and development plans
Pharmaceutical companies
Sub-action 6.1

Prioritize PADO products in research and development plans

Pharmaceutical companies

ViiV has committed additional resources in Pediatrics with the appointment of a Head of Pediatric Strategy (Bill Collier) who has convened a cross-functional team to address possible ways to accelerate development of DTG for pediatrics.

-

Milestone 6.1.1

Review ARV portfolio, prioritize PADO products and communicate changes with stakeholders by IAC July 2018.

-

-

-

Milestone 6.1.2

Demonstrate timely implementation of PADO priorities as part of their paediatric portfolio (by 2020).

-

-

-

Document (s)

-

-

-

-

Sub-Actions & Milestones

Updates

Notes

Responsible